Prof Martine Piccart speaks to ecancer at the 2019 San Antonio Breast Cancer Symposium about the updated six-year results from the APHINITY trial.
She gives a summary of the previous analyses, in which a statistically significant improvement in invasive disease-free survival, favouring the pertuzumab plus trastuzumab and chemotherapy arm.
Prof Piccart explains that this benefit has strengthened in the past six years and notes that a 4.5 percent absolute benefit has been seen in the node-positive patients. In addition, no new cardiac toxicities were detected.
She adds that the benefit of pertuzumab is independent from hormone-receptor status.
Prof Piccart believes that the achievement of this data is another step forward in eradicating this disease.
Watch the press conference here.
Read more about the study here.